Plaintiffs Ask Court To Revisit Neurontin Ruling

By Erin Coe

Law360, New York (February 09, 2010, 6:15 PM ET) -- A group of plaintiffs has urged a federal court to reconsider a ruling that threw out Guardian Life Insurance Co. and Aetna Inc.’s claims in multidistrict litigation accusing Pfizer Inc. of improperly marketing anti-epilepsy drug Neurontin for off-label uses.

The class plaintiffs filed a bid with the U.S. District Court for the District of Massachusetts on Monday, claiming the court’s Jan. 8 ruling may have adopted a sweeping rule of law that could devastate private litigants’ ability to protect affordable health care from fraudulent marketing scams...
To view the full article, take a free trial now.

Already a subscriber? Click here to login

You must correct or enter the following before you can submit this form:

All fields required

  5. Required

Only Law360 gives you:

Non-stop coverage of high-stakes litigation across 30 practices

Real-time tracking and reports on 10,000+ companies, firms and industries

Over 80,000 attorney profiles with neutral data collected from active lawsuits

Research tools to find cases, court documents, attorneys and companies

Customized feeds and alerts that can easily be shared with colleagues

In-depth expert analysis from high-profile attorneys at top firms

Access to our vault with over 75,000 original articles